Physician profile
Andrew Mcclellan
NPI 1588935217
$4,812.48
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,483 · 2021: $24.90 · 2022: $509 · 2023: $1,444 · 2024: $1,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $1,200 · Food and Beverage: $837 · Consulting Fee: $724 · Education: $34.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $1,200.00 |
| Food and Beverage | $837.48 |
| Consulting Fee | $724.00 |
| Education | $34.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $1,459.07 | 2020 | |
| Alimera Sciences, INC. | $1,200.00 | 2023 | Iluvien |
| Regeneron Healthcare Solutions, INC. | $1,068.26 | 2022-2024 | Eylea Hd, Eylea |
| Novartis Pharmaceuticals Corporation | $397.89 | 2022 | |
| Genentech USA, INC. | $135.79 | 2022-2024 | Vabysmo |
| Alcon Vision LLC | $128.56 | 2024 | |
| Astellas Pharma US INC | $116.79 | 2023-2024 | Izervay |
| Abbvie INC. | $75.04 | 2022-2024 | |
| Harrow Eye, LLC | $69.68 | 2024 | Iheezo, Triesence |
| Apellis Pharmaceuticals, INC. | $55.60 | 2023-2024 | Syfovre |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $48.84 | 2020-2021 | |
| Coherus Oncology, INC. | $30.49 | 2024 | |
| Sandoz INC. | $26.47 | 2024 | Cimerli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Mcclellan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.